Sun Pharma's Bold Acquisition: Elevating Global Presence with Organon Deal

In a major strategic move, Sun Pharmaceutical Industries Ltd has announced a definitive agreement to acquire US-based healthcare company Organon & Co. for $14.00 per share in an all-cash transaction. This acquisition values Organon at an enterprise valuation of $11.75 billion, causing a 7% surge in Sun Pharma's shares, propelling it to the top of the Nifty 50 index during Monday's trading session.

The acquisition enhances Sun Pharma's portfolio by integrating Organon's established brands and branded generics, while marking its entry into the biosimilars market as a top-10 global player. The deal, expected to close in early 2027, requires regulatory and shareholder approvals. Organon, which emerged from Merck in 2021, specializes in women's health and boasts a diverse range of products commercialized in 140 countries.

Upon completion, the merged entity will rank Sun Pharma among the top 25 global pharmaceuticals, projecting combined revenue of $12.4 billion. It will emerge as a top-3 company in global women's health and the 7th largest in biosimilars, with operations across 150 countries. Kirti Ganorkar, Managing Director of Sun Pharma, emphasized the acquisition as a logical step in expanding global business, underscoring the synergy and revenue potential anticipated from this strategic deal.

(With inputs from agencies.)